임상시험 시장 규모, 점유율, 동향 분석 보고서 : Phase별, 연구 디자인별, 적응증별, 연구 디자인에 의한 적응증별, 서비스별, 스폰서별, 지역별, 부문 예측(2025-2033년)

Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication, By Study Design, By Indication By Study Design, By Service, By Sponsor, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,876,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,368,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,351,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

임상시험 시장 요약

세계의 임상시험 시장 규모는 2024년 845억 4,000만 달러로 평가되었고, 2033년까지 1,584억 1,000만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지의 CAGR은 7.48%를 나타낼 것으로 전망됩니다. 시장 성장은 만성 및 희귀질환의 유병률 증가, 정밀의료 및 생명 공학의 발전, 분산 및 가상 시험 확대, 제약 회사 및 생명 공학 회사의 R&D 투자 증가로 인한 것입니다.

시장 성장은 COVID-19 팬데믹 이후 급증했습니다. 여러 기업이 COVID-19 환자의 부담 경감을 향해 신규 약제 개발에 다액의 투자를 실시했습니다. 2020년에 Synairgen plc와 Parexel은 COVID-19 치료제 인터페론 베타(IFN-β)의 3상 시험에서 협력했습니다. 이러한 CRO(의약품 개발 수탁기관)에 의한 전략적 이니셔티브가 시장 수익의 성장을 뒷받침했습니다. 게다가 기술의 급속한 진화, 만성질환의 만연, 임상시험의 세계화, 연구활동 실시를 위한 CRO 수요 증가 등의 요인에 의해 시장의 성장이 전망되고 있습니다.

게다가 향후 실시되는 임상시험이나 진행중인 임상시험의 실시방법에 있어서 큰 변화도 시장 성장에 기여하는 요인의 하나입니다. 미국 식품의약국(FDA), 유럽의약청(EMA), 미국 국립위생연구소(NIH), 중국 국가약품감독관리국 등 여러 규제당국이 분산형 임상시험 및 가상서비스 실시를 지원하기 위해 시험 실시에 관한 다양한 가이드라인을 발표했습니다. 세계적인 R&D 활동의 현재 상태와 수많은 새로운 치료 옵션의 필요성으로 신속화 임상시험의 도입도 진행되고 있습니다. 따라서 앞서 언급한 요인이 임상시험 시장의 성장에 새로운 기회를 가져올 것으로 예측됩니다.

또한 CRO 서비스를 활용하면 제조업체와 스폰서가 핵심 생산 능력을 강화하고 내부 업무 프로세스를 최적화하는 데 자원을 집중할 수 있습니다. 신약 개발에서 시판 후 조사에 이르기까지 다양한 서비스를 제공함으로써 중소규모의 제약 및 바이오테크놀러지 기업은 연구개발을 외부 위탁하는 옵션을 얻어 인프라 투자를 삭감할 수 있어 프로세스가 더욱 간소화되었습니다. 예를 들어, 2023년 11월에는 시네오스 헬스사가 고브로드 헬스케어 그룹과 제휴 계약을 체결했습니다. 이 협업을 통해 회사의 임상시험 능력은 중국에서 더 광범위한 치료 영역으로 확장되었습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 임상시험 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
• 시장 성장 억제요인 분석
  • 시장 과제 분석
• 연구개발비 분석
  • 주요 스폰서별 R&D 투자 분석(2021-2024년)
  • 벤처캐피탈과 정부의 자금조달 시나리오
• 임상시험 디자인 분석
• 업계 생태계 분석
• 기술의 상황
• 가격 분석
• 임상시험 건수 분석(2024년)
  • 지역별 임상시험 총수(2024년)
  • 임상시험의 총수(Phase별)(2024년)
  • 임상시험의 총수(연구 디자인별)(2024년)
  • 주요 적응증별 임상시험 총수(2024년)
• 임상시험 시장 분석 도구
  • Porter's Five Forces 분석
  • SWOT 분석에 의한 PESTEL

제4장 임상시험 시장 : 위상 추정 및 동향 분석

• 부문 대시보드
• 임상시험 시장 : 위상 변동 분석
• Phase별(2021-2033년)
• Phase I
• Phase II
• Phase III
• Phase IV

제5장 임상시험 시장 : 연구 디자인의 추정 및 동향 분석

• 부문 대시보드
• 임상시험 시장 : 연구 디자인변동분석
• 연구 디자인별(2021-2033년)
• 중재적
• 관찰적
• 확대 접근

제6장 임상시험 시장 : 적응증의 추정 및 동향 분석

• 부문 대시보드
• 임상시험 시장 : 적응증 변동 분석
• 증상별(2021-2033년)
• 자가면역/염증
  • 류마티스 관절염
  • 다발성 경화증
  • 골관절염
  • 과민성 대장 증후군(IBS)
  • 기타
• 통증 관리
  • 만성 통증
  • 급성 통증
• 종양학
  • 혈액암
  • 고형 종양
  • 기타
• 중추신경계 질환
  • 간질
  • 파킨슨병(PD)
  • 헌팅턴병
  • 뇌졸중
  • 외상성 뇌손상(TBI)
  • 근위축성 측삭 경화증(ALS)
  • 근육 재생
  • 기타
• 당뇨병
• 비만
• 심혈관 질환
• 기타

제7장 임상시험 시장 : 연구 디자인에 의한 적응증의 추정 및 동향 분석

• 부문 대시보드
• 임상시험 시장 : 연구 설계에 의한 적응증 변동 분석
• 연구 디자인에 의한 적응증별(2021-2033년)
• 자가면역/염증
  • 중재적 임상시험
  • 관찰 연구
  • 확대 접근 시험
• 통증 관리
  • 중재적 임상시험
  • 관찰 연구
  • 확대 접근 시험
• 종양학
  • 중재적 임상시험
  • 관찰 연구
  • 확대 접근 시험
• 중추신경계 질환
  • 중재적 임상시험
  • 관찰 연구
  • 확대 접근 시험
• 당뇨병
  • 중재적 임상시험
  • 관찰 연구
  • 확대 접근 시험
• 비만
  • 중재적 임상시험
  • 관찰 연구
  • 확대 접근 시험
• 심혈관 질환
  • 중재적 임상시험
  • 관찰 연구
  • 확대 접근 시험
• 기타
  • 중재적 임상시험
  • 관찰 연구
  • 확대 접근 시험

제8장 임상시험 시장 : 서비스의 추정 및 동향 분석

• 부문 대시보드
• 임상시험 시장 : 서비스 변동 분석
• 서비스별(2021-2033년)
• 프로토콜 설계
• 사이트 선정
• 환자 모집
• 실험실 서비스
• 분석 검사 서비스
• 임상시험 데이터 관리 서비스
• 기타

제9장 임상시험 시장 : 스폰서의 추정 및 동향 분석

• 부문 대시보드
• 임상시험 시장 : 스폰서 변동 분석
• 스폰서 제공(2021-2033년)
• 제약 및 바이오의약품 기업
• 의료기기 기업
• 기타

제10장 임상시험 시장 : 지역의 추정 및 동향 분석

• 지역 전망
• 임상시험 시장 : 지역 변동 분석
• 지역별(2021-2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 콜롬비아
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트
  • 카타르
  • 오만

제11장 경쟁 구도

• 기업 분류
  • 이노베이터
  • 마켓 리더
  • 신흥기업
• 기업 시장 평가 분석(기업 히트 맵 분석, 2024년)
• 주요 기업 프로파일
  • Pharmaceutical Product Development, INC.(Thermo Fisher Scientific, Inc.)
  • ICON plc
  • Charles River Laboratories International, Inc.
  • IQVIA
  • SYNEOS HEALTH
  • SGS SA
  • PAREXEL International Corporation
  • Wuxi AppTec, Inc
  • Chiltern International Ltd(Laboratory Corporation of America)
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Pfizer
  • Clinipace(Caidya)
• 기타 주요 시장 기업 목록

KTH

영문 목차

영문목차

Clinical Trials Market Summary

The global clinical trials market size was estimated at USD 84.54 billion in 2024 and is projected to reach USD 158.41 billion by 2033, growing at a CAGR of 7.48% from 2025 to 2033. The growth of the market is driven by rising prevalence of chronic and rare diseases, advancements in precision medicine and biotechnology, expansion of decentralized and virtual trials, and growing R&D investments by pharmaceutical and biotech companies.

The market growth spiked post COVID-19 pandemic. Several companies invested heavily in novel drug development to minimize COVID-19 patient burden. In 2020, Synairgen plc and Parexel collaborated on a Phase III study of Interferon-beta (IFN-beta) treatment for COVID-19. Such strategic initiatives by CROs boosted market revenue growth. Furthermore, the market is expected to grow owing to factors such as rapid technological evolution, prevalence of chronic diseases, globalization of clinical trials, and a rise in demand for CROs for conducting research activities.

In addition, significant changes in the ways of conducting upcoming or ongoing clinical trials is also one of the factors contributing to market growth. Regulatory agencies including the U.S. FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and China's National Medical Products Administration among several others issued various guidelines for conducting trials to support the implementation of decentralized clinical trials and virtual services. The current scenario for research and development activities across the globe and the need for several new treatment options have also led to the adoption of fast-track clinical trials. Thus, aforementioned factors are estimated to open new opportunities to the clinical trials market growth.

Furthermore, the utilization of CRO services enables manufacturers and sponsors to focus their resources on strengthening core production capabilities and optimizing in-house operational processes. The availability of the vast array of services from drug discovery to post marketing surveillance has further simplified processes for mid-size & small-scale pharmaceutical and biotechnological organizations by providing them the option to outsource research and development activities to reduce infrastructure investment. For instance, in November 2023, Syneos Health entered into a collaboration agreement with GoBroad Healthcare Group. This collaborative initiative extended the company's clinical trial capabilities into a more extensive array of therapeutic areas in China.

Global Clinical Trials Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and region.

• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Phase IV
• Study Design Outlook (Revenue, USD Million, 2021 - 2033)
• Interventional Trials
• Observational Trials
• Expanded Access Trials
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Autoimmune/Inflammation
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Osteoarthritis
  • Irritable Bowel Syndrome (IBS)
  • Others
• Pain Management
  • Chronic Pain
  • Acute Pain
• Oncology
  • Blood Cancer
  • Solid Tumors
  • Others
• CNS Conditions
  • Epilepsy
  • Parkinson's Disease (PD)
  • Huntington's Disease
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Muscle Regeneration
  • Others
• Diabetes
• Obesity
• Cardiovascular Diseases
• Others
• Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
• Autoimmune/Inflammation
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
• Pain Management
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
• Oncology
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
• CNS Conditions
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
• Diabetes
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
• Obesity
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
• Cardiovascular Diseases
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
• Others
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Analytical Testing Services
• Clinical Trial Data Management Services
• Others
• Sponsor Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • India
  • China
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
  • Columbia
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Trials Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Research and Development Activities
    • 3.2.1.2. Adoption of New Technology in Clinical Research
    • 3.2.1.3. Increasing Prevalence of Chronic Diseases
    • 3.2.1.4. Globalization of Clinical Trials
    • 3.2.1.5. Shift Toward Personalized Medicine
• 3.3. Market Restraint Analysis
  • 3.3.1.1. Stringent Regulations in New Drug Development
  • 3.3.1.2. Lack of Skilled Workforce in Clinical Research
  • 3.3.2. Market Challenge Analysis
    • 3.3.2.1. Rising Cost of Clinical Trial
• 3.4. R&D Spending Analysis
  • 3.4.1. R&D Investment Analysis, by Key Sponsors (2021 - 2024)
  • 3.4.2. Venture Capital & Government Funding Scenario
• 3.5. Clinical Trials Design Analysis
• 3.6. Industry Ecosystem Analysis
• 3.7. Technology Landscape
• 3.8. Pricing Analysis
• 3.9. Clinical Trial Volume Analysis, 2024
  • 3.9.1. Total Number of Clinical Trials, By Region (2024)
  • 3.9.2. Total Number of Clinical Trials, By Phase (2024)
  • 3.9.3. Total Number of Clinical Trials, By Study Design (2024)
  • 3.9.4. Total Number of Clinical Trials, By Key Indication (2024)
• 3.10. Clinical Trials Market Analysis Tools
  • 3.10.1. Porter's Five Forces Analysis
  • 3.10.2. PESTEL by SWOT Analysis

Chapter 4. Clinical Trials Market: Phase Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Clinical Trials Market: Phase Movement Analysis
• 4.3. Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
• 4.4. Phase I
  • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Phase II
  • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Phase III
  • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Phase IV
  • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Clinical Trials Market: Study Design Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Clinical Trials Market: Study Design Movement Analysis
• 5.3. Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
• 5.4. Interventional
  • 5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Observational
  • 5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Expanded Access
  • 5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Clinical Trials Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Clinical Trials Market: Indication Movement Analysis
• 6.3. Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• 6.4. Autoimmune/Inflammation
  • 6.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Rheumatoid Arthritis
    • 6.4.2.1. Rheumatoid Arthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Multiple Sclerosis
    • 6.4.3.1. Multiple Sclerosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Osteoarthritis
    • 6.4.4.1. Osteoarthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Irritable Bowel Syndrome (IBS)
    • 6.4.5.1. Irritable Bowel Syndrome (IBS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Pain Management
  • 6.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Chronic Pain
    • 6.5.2.1. Chronic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Acute Pain
    • 6.5.3.1. Acute Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Oncology
  • 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Blood Cancer
    • 6.6.2.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Solid Tumors
    • 6.6.3.1. Solid Tumors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. Others
    • 6.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. CNS Conditions
  • 6.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Epilepsy
    • 6.7.2.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Parkinson's Disease (PD)
    • 6.7.3.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. Huntington's Disease
    • 6.7.4.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Stroke
    • 6.7.5.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.6. Traumatic Brain Injury (TBI)
    • 6.7.6.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.7. Amyotrophic Lateral Sclerosis (ALS)
    • 6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.8. Muscle Regeneration
    • 6.7.8.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.9. Others
    • 6.7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Diabetes
  • 6.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Obesity
  • 6.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Cardiovascular Diseases
  • 6.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.11. Others
  • 6.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Clinical Trials Market: Indication by Study Design Movement Analysis
• 7.3. Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021 - 2033 (USD Million)
• 7.4. Autoimmune/Inflammation
  • 7.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. Interventional Trials
    • 7.4.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Observational Trials
    • 7.4.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Expanded Access Trials
    • 7.4.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Pain Management
  • 7.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Interventional Trials
    • 7.5.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Observational Trials
    • 7.5.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Expanded Access Trials
    • 7.5.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Oncology
  • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Interventional Trials
    • 7.6.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Observational Trials
    • 7.6.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. Expanded Access Trials
    • 7.6.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. CNS Conditions
  • 7.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Interventional Trials
    • 7.7.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Observational Trials
    • 7.7.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. Expanded Access Trials
    • 7.7.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Diabetes
  • 7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. Interventional Trials
    • 7.8.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Observational Trials
    • 7.8.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. Expanded Access Trials
    • 7.8.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Obesity
  • 7.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.2. Interventional Trials
    • 7.9.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.3. Observational Trials
    • 7.9.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.4. Expanded Access Trials
    • 7.9.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Cardiovascular Diseases
  • 7.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10.2. Interventional Trials
    • 7.10.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10.3. Observational Trials
    • 7.10.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10.4. Expanded Access Trials
    • 7.10.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.11. Others
  • 7.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11.2. Interventional Trials
    • 7.11.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11.3. Observational Trials
    • 7.11.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11.4. Expanded Access Trials
    • 7.11.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Clinical Trials Market: Service Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Clinical Trials Market: Service Movement Analysis
• 8.3. Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
• 8.4. Protocol Designing
  • 8.4.1. Protocol Designing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Site Identification
  • 8.5.1. Site Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Patient Recruitment
  • 8.6.1. Patient Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Laboratory Services
  • 8.7.1. Laboratory Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Analytical Testing Services
  • 8.8.1. Analytical Testing Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.9. Clinical Trial Data Management Services
  • 8.9.1. Clinical Trial Data Management Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.10. Others
  • 8.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Clinical Trials Market: Sponsor Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Clinical Trials Market: Sponsor Movement Analysis
• 9.3. Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
• 9.4. Pharmaceutical & Biopharmaceutical Companies
  • 9.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Medical Device Companies
  • 9.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Others
  • 9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Clinical Trials Market: Regional Estimates & Trend Analysis

• 10.1. Regional Outlook
• 10.2. Clinical Trials Market: Regional Movement Analysis
• 10.3. Clinical Trials Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
• 10.4. North America
  • 10.4.1. North America Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.2. U.S.
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Competitive Scenario
    • 10.4.2.3. Regulatory Framework
    • 10.4.2.4. U.S. Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.3. Canada
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Competitive Scenario
    • 10.4.3.3. Regulatory Framework
    • 10.4.3.4. Canada Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.4. Mexico
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Competitive Scenario
    • 10.4.4.3. Regulatory Framework
    • 10.4.4.4. Canada Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.5. Europe
  • 10.5.1. Europe Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.2. UK
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Competitive Scenario
    • 10.5.2.3. Regulatory Framework
    • 10.5.2.4. UK Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.3. Germany
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Competitive Scenario
    • 10.5.3.3. Regulatory Framework
    • 10.5.3.4. Germany Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.4. France
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Competitive Scenario
    • 10.5.4.3. Regulatory Framework
    • 10.5.4.4. France Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.5. Italy
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Competitive Scenario
    • 10.5.5.3. Regulatory Framework
    • 10.5.5.4. Italy Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.6. Spain
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Competitive Scenario
    • 10.5.6.3. Regulatory Framework
    • 10.5.6.4. Spain Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.7. Denmark
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Competitive Scenario
    • 10.5.7.3. Regulatory Framework
    • 10.5.7.4. Denmark Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.8. Sweden
    • 10.5.8.1. Key Country Dynamics
    • 10.5.8.2. Competitive Scenario
    • 10.5.8.3. Regulatory Framework
    • 10.5.8.4. Sweden Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.9. Norway
    • 10.5.9.1. Key Country Dynamics
    • 10.5.9.2. Competitive Scenario
    • 10.5.9.3. Regulatory Framework
    • 10.5.9.4. Norway Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.6. Asia Pacific
  • 10.6.1. Asia Pacific Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6.2. Japan
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Competitive Scenario
    • 10.6.2.3. Regulatory Framework
    • 10.6.2.4. Japan Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6.3. China
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Competitive Scenario
    • 10.6.3.3. Regulatory Framework
    • 10.6.3.4. China Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6.4. India
    • 10.6.4.1. Key Country Dynamics
    • 10.6.4.2. Competitive Scenario
    • 10.6.4.3. Regulatory Framework
    • 10.6.4.4. India Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6.5. South Korea
    • 10.6.5.1. Key Country Dynamics
    • 10.6.5.2. Competitive Scenario
    • 10.6.5.3. Regulatory Framework
    • 10.6.5.4. South Korea Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6.6. Australia
    • 10.6.6.1. Key Country Dynamics
    • 10.6.6.2. Competitive Scenario
    • 10.6.6.3. Regulatory Framework
    • 10.6.6.4. Australia Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6.7. Thailand
    • 10.6.7.1. Key Country Dynamics
    • 10.6.7.2. Competitive Scenario
    • 10.6.7.3. Regulatory Framework
    • 10.6.7.4. Thailand Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.7. Latin America
  • 10.7.1. Latin America Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7.2. Brazil
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Competitive Scenario
    • 10.7.2.3. Regulatory Framework
    • 10.7.2.4. Brazil Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7.3. Argentina
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Competitive Scenario
    • 10.7.3.3. Regulatory Framework
    • 10.7.3.4. Argentina Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7.4. Columbia
    • 10.7.4.1. Key Country Dynamics
    • 10.7.4.2. Competitive Scenario
    • 10.7.4.3. Regulatory Framework
    • 10.7.4.4. Columbia Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.8. Middle East & Africa
  • 10.8.1. Middle East & Africa Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.8.2. South Africa
    • 10.8.2.1. Key Country Dynamics
    • 10.8.2.2. Competitive Scenario
    • 10.8.2.3. Regulatory Framework
    • 10.8.2.4. South Africa Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.8.3. Saudi Arabia
    • 10.8.3.1. Key Country Dynamics
    • 10.8.3.2. Competitive Scenario
    • 10.8.3.3. Regulatory Framework
    • 10.8.3.4. Saudi Arabia Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.8.4. UAE
    • 10.8.4.1. Key Country Dynamics
    • 10.8.4.2. Competitive Scenario
    • 10.8.4.3. Regulatory Framework
    • 10.8.4.4. UAE Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.8.5. Kuwait
    • 10.8.5.1. Key Country Dynamics
    • 10.8.5.2. Competitive Scenario
    • 10.8.5.3. Regulatory Framework
    • 10.8.5.4. Kuwait Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.8.6. Qatar
    • 10.8.6.1. Key Country Dynamics
    • 10.8.6.2. Competitive Scenario
    • 10.8.6.3. Regulatory Framework
    • 10.8.6.4. Qatar Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.8.7. Oman
    • 10.8.7.1. Key Country Dynamics
    • 10.8.7.2. Competitive Scenario
    • 10.8.7.3. Regulatory Framework
    • 10.8.7.4. Oman Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Company Categorization
  • 11.1.1. Innovators
  • 11.1.2. Market Leaders
  • 11.1.3. Emerging Players
• 11.2. Company Market Assessment Analysis, 2024 (Company Heat Map Analysis)
• 11.3. Key Company Profiles
  • 11.3.1. Pharmaceutical Product Development, INC. (Thermo Fisher Scientific, Inc.)
    • 11.3.1.1. Company Overview
    • 11.3.1.2. Financial Performance
    • 11.3.1.3. Service Benchmarking
    • 11.3.1.4. Strategic Initiatives
  • 11.3.2. ICON plc
    • 11.3.2.1. Company Overview
    • 11.3.2.2. Financial Performance
    • 11.3.2.3. Service Benchmarking
    • 11.3.2.4. Strategic Initiatives
  • 11.3.3. Charles River Laboratories International, Inc.
    • 11.3.3.1. Company Overview
    • 11.3.3.2. Financial Performance
    • 11.3.3.3. Service Benchmarking
    • 11.3.3.4. Strategic Initiatives
  • 11.3.4. IQVIA
    • 11.3.4.1. Company Overview
    • 11.3.4.2. Financial Performance
    • 11.3.4.3. Service Benchmarking
    • 11.3.4.4. Strategic Initiatives
  • 11.3.5. SYNEOS HEALTH
    • 11.3.5.1. Company Overview
    • 11.3.5.2. Financial Performance
    • 11.3.5.3. Service Benchmarking
    • 11.3.5.4. Strategic Initiatives
  • 11.3.6. SGS SA
    • 11.3.6.1. Company Overview
    • 11.3.6.2. Financial Performance
    • 11.3.6.3. Service Benchmarking
    • 11.3.6.4. Strategic Initiatives
  • 11.3.7. PAREXEL International Corporation
    • 11.3.7.1. Company Overview
    • 11.3.7.2. Financial Performance
    • 11.3.7.3. Service Benchmarking
    • 11.3.7.4. Strategic Initiatives
  • 11.3.8. Wuxi AppTec, Inc
    • 11.3.8.1. Company Overview
    • 11.3.8.2. Financial Performance
    • 11.3.8.3. Service Benchmarking
    • 11.3.8.4. Strategic Initiatives
  • 11.3.9. Chiltern International Ltd (Laboratory Corporation of America)
    • 11.3.9.1. Company Overview
    • 11.3.9.2. Financial Performance
    • 11.3.9.3. Service Benchmarking
    • 11.3.9.4. Strategic Initiatives
  • 11.3.10. Eli Lilly and Company
    • 11.3.10.1. Company Overview
    • 11.3.10.2. Financial Performance
    • 11.3.10.3. Service Benchmarking
    • 11.3.10.4. Strategic Initiatives
  • 11.3.11. Novo Nordisk A/S
    • 11.3.11.1. Company Overview
    • 11.3.11.2. Financial Performance
    • 11.3.11.3. Service Benchmarking
    • 11.3.11.4. Strategic Initiatives
  • 11.3.12. Pfizer
    • 11.3.12.1. Company Overview
    • 11.3.12.2. Financial Performance
    • 11.3.12.3. Service Benchmarking
    • 11.3.12.4. Strategic Initiatives
  • 11.3.13. Clinipace (Caidya)
    • 11.3.13.1. Company Overview
    • 11.3.13.2. Financial Performance
    • 11.3.13.3. Service Benchmarking
    • 11.3.13.4. Strategic Initiatives
• 11.4. List of Other Key Market Players

관련자료